Myriad Pharmaceuticals announced last week that it will suspend further development of its anti-HIV drug, MPC-4326, and will instead focus on developing anti-cancer drugs. The company attributed the change to strategic and business reasons.

Patrick Burke, Vice President of Corporate and Business Development at Myriad Pharmaceuticals, stated in an interview with The AIDS Beacon that Myriad is currently looking for a partner to advance MPC-4326 and an additional novel HIV drug. This partner would then acquire rights to advance the drugs further.

Myriad’s Phase 2 clinical trial into the efficacy…